2,540 reports of this reaction
8.7% of all RUCAPARIB reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for RUCAPARIB, manufactured by pharmaand GmbH. There are 2,540 FDA adverse event reports linking RUCAPARIB to FATIGUE. This represents approximately 8.7% of all 29,211 adverse event reports for this drug.
Patients taking RUCAPARIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among RUCAPARIB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for RUCAPARIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,540 FDA reports for RUCAPARIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 8.7% of all adverse event reports for RUCAPARIB, making it one of the most commonly reported side effect.
If you experience fatigue while taking RUCAPARIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.